IPAR

Public Assessment Report for a
Medicinal Product for Human Use

Scientific Discussion

Abendur 2.5 mg tablets
Bendroflumethiazide
PA23163/004/001

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

CONTENTS

I. INTRODUCTION

II. QUALITY ASPECTS

III. NON-CLINICAL ASPECTS

IV. CLINICAL ASPECTS

V. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

VI. REVISION DATE

VII. UPDATE

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the HPRA has granted a marketing authorisation for Abendur 2.5mg & 5mg Tablets (Bendroflumethiazide), from Ascot Laboratories (Ireland) Ltd on 16th January 2026 indicated for the treatment of oedema and hypertension.

This application for a national marketing authorisation was submitted in accordance with Article 10(1) of Directive 2001/83/EC and is referred to as a generic application. Abendur 2.5mg & 5mg Tablets are generic versions of Salures 2.5mg and 5mg tablets of Pfizer AB, authorised in Sweden since 26/05/1961.

Abendur 2.5mg & 5mg Tablets are prescription only, for supply through pharmacy and for promotion to healthcare professionals only.

The Summary of Product Characteristics for (SmPC) for this medicinal product is available on the HPRA's website at www.hpra.ie.

Name of the product	Abendur 2.5 mg tablets
Name(s) of the active substance(s) (INN)	Bendroflumethiazide
Pharmacotherapeutic classification (ATC Code)	C03AA01
Pharmaceutical form and strength(s)	2.5mg Tablet
Marketing Authorisation Number(s) in Ireland (PA)	PA23163/004/001
Marketing Authorisation Holder	Ascot Laboratories (Ireland) Ltd Clarity House, Belgard Road, Tallaght, Dublin 24, D24 Y6DF Ireland

II. QUALITY ASPECTS

II.1. Introduction

This application is for Abendur 2.5 mg Tablets and Abendur 5 mg Tablets.

II.2 Drug substance

The active substance is bendroflumethiazide, an established active substance described in the European Pharmacopoeia, and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP)

The active substance specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided.

II.3 Medicinal product

P.1 Composition

Abendur 2.5 mg Tablets each contain 2.5 mg bendroflumethiazide.
Abendur 5 mg Tablets each contain 5 mg bendroflumethiazide.

The excipients in the medicinal product are listed in section 6.1 of the SmPC.
A visual description of the product is included in section 3 of the SmPC.

P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of good manufacturing practice (GMP) at suitably qualified manufacturing sites.

The manufacturing process has been validated according to relevant European/ICH guidelines and the process is considered to be sufficiently validated.

P.4 Control of Other Substances (Excipients/*Ancillary Substances*)

All ingredients comply with the Ph. Eur.

P.5 Control of Finished Product

The Finished Product Specification is based on the pharmacopoeial monograph for Tablets, and the tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production site(s) have been provided, and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

P.6 Packaging material

The approved packaging for this product is described in section 6.5 of the SmPC.

Evidence has been provided that the packaging complies with Ph. Eur./EU legislation for use with foodstuffs requirements.

P.7 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC.

II.4 Discussion on Chemical, Pharmaceutical and Biological Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of Abendur 2.5 mg Tablets or Abendur 5 mg Tablets.

III. NON-CLINICAL ASPECTS

III.1 Introduction

This active substance is a generic formulation of Salures 2.5mg and 5mg tablets of Pfizer AB on the European market since 1961. No new preclinical data have been submitted. As such, no pre-clinical assessment has been made on the application. This is acceptable for this type of application.

III.2 Ecotoxicity/environmental risk assessment

Bendroflumethiazide PEC surfacewater value is below the action limit of 0.01 µg/L and is not a PBT substance as log Kow does not exceed 4.5.
In addition, bendroflumethiazide is already used in existing marketed products and no significant increase in environmental exposure is anticipated

III.3 Discussion on the non-clinical aspects

The pharmacodynamic, pharmacokinetic and toxicological properties of bendroflumethiazide are well known. As bendroflumethiazide is a widely used, well-known active substance, the applicant has not provided additional studies and further studies are not required.

IV. CLINICAL ASPECTS

IV.1 Introduction

Bendroflumethiazide is a well-known active substance with established efficacy and tolerability.

The content of the SmPCs approved during the national procedure are similar to what is accepted for the reference products Salures 2.5mg and 5mg tablets of Pfizer AB, authorised in Sweden since 26/05/1961.

For this generic application, the applicant has submitted one bioequivalence study in which the pharmacokinetic profile of the test product (referred to as Bendroflumethiazide tablets 5mg is compared with the pharmacokinetic profile of the reference product Salures 5mg tablets (bendroflumethiazde) of Pfizer AB.

An open-label, randomised, balanced, two treatment, two period, two sequence, two-way crossover, single dose bioequivalence study was carried out under fasting conditions.

Based on the pharmacokinetic parameters of the active substance bendroflumethiazide, the reference tablet Salures 5mg tablets marketed by Pfizer AB and test tablet Bendroflumethiazide 5mg are bioequivalent with extent to the rate and extent of absorption and fulfil the bioequivalence requirements outlined in the CHMP Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1/Corr).

The 5mg tablets are dose proportional with the 2.5mg tablets. The pharmacokinetics of the active substance bendroflumethiazide are linear in the 2.5mg-10mg range. The applicant has provided justification for a biowaiver for the 2.5mg strength and therefore the results of the bioequivalence study performed with the 5mg tablet also apply to the 2.5mg strength.

The HPRA has been assured that GCP standards were followed in an appropriate manner in the studies conducted.

IV.2 Pharmacokinetics

Absorption: Bendroflumethiazide has been reported to be completely absorbed from the gastrointestinal tract. Diuresis is initiated in about 2 hours and lasts for 12 – 18 hours or longer.

Distribution: Bendroflumethiazide is more than 90% bound to plasma proteins.

Metabolism: There are indications that it is fairly extensively metabolised. Peak plasma levels are reached in 2 hours and a plasma half – life of between 3 and 8.5 hours on average.

Elimination: About 30% is excreted unchanged in the urine with the remainder excreted as uncharacterized metabolites.

IV.3 Pharmacodynamics

Pharmacotherapeutic group: Thiazide diuretics ATC CODE; CO3AA01

Bendroflumethiazide is a thiazide diuretic which reduces the reabsorption of electrolytes from the renal tubules, thereby increasing the excretion of sodium and chloride ions, and consequently of water. Bendroflumethiazide exerts its diuretic effect in about 2 hours and this lasts for 12 to 18 hours or longer.

Bendroflumethiazide has, like other thiazides, a lowering effect on blood pressure, which is considered to be due to sodium depletion; and it also enhances the effects of other antihypertensive agents. Bendroflumethiazide is used in oedema associated with congestive heart failure, renal and hepatic disorders.

IV.4 Clinical Efficacy

The clinical efficacy of bendroflumethiazide is well established. No additional efficacy clinical studies to demonstrate efficacy have been included in the application. This is appropriate for this type of application.

IV.5 Clinical Safety

The clinical safety of bendroflumethiazide is well established. No additional safety clinical studies to demonstrate safety have been included in the application. This is appropriate for this type of application.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

A risk management plan was submitted, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Abendur 2.5mg & 5mg Tablets.

Routine pharmacovigilance activities and risk minimisation measures are considered sufficient.

With regard to periodic safety update report submission, the applicant should follow the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

IV.6 Discussion on the clinical aspects

Sufficient clinical information has been submitted by the applicant to support authorisation of this medicinal product.

The benefit/risk profile of the product is considered to be positive.

V. OVERALL CONCLUSIONS

Abendur 2.5mg & 5mg Tablets, from Ascot Laboratories (Ireland) Ltd are generic forms of Salures 2.5mg and 5mg tablets of Pfizer AB, authorised in Sweden since 26/05/1961. Salures 2.5mg and 5mg tablets are well-known medicinal products with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

Bioequivalence has been shown to be in compliance with the CHMP guidance documents.
The SmPCs are consistent with those of the reference product.

The HPRA, on the basis of the data submitted considered that Abendur 2.5mg & 5mg Tablets demonstrated bioequivalence with the reference products as well as a satisfactory risk/benefit profile and therefore granted a marketing authorisation.

VII. UPDATES

SCOPE	PROCEDURE NUMBER	PRODUCT INFORMATION AFFECTED	DATE OF START OF PROCEDURE	DATE OF END OF PROCEDURE
New National	CRN008MTK	SmPC, IPAR and Pil	16th January 2026	15th January 2031